Image de couverture de livre

Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Giacomo Loseto, Maria Chiara Tisi, Antonella Anastasia, Alessandro Broccoli, Ilaria Del Giudice, Caterina Patti, Benedetta Puccini, Caterina Stelitano, Vittorio Zilioli, Stefano Luminari
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Hematological Oncology
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Survival Benefit of Relmacabtagene Autoleucel Versus Usual Care in Relapsed/Refractory Follicular Lymphoma: A Matching‐Adjusted Indirect Analysis
par: Fenghua Gao, et autres
Publié: (2025)

Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B‐Cell Lymphoma in the Compassionate Use Program in Italy
par: Pier Luigi Zinzani, et autres
Publié: (2025)

A SWOT‐Consensus for CAR‐T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection
par: Monia Marchetti, et autres
Publié: (2025)

Real‐life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience
par: Vittorio Ruggero Zilioli, et autres
Publié: (2024)

Comparative Effectiveness of R‐miniCOMP Versus R‐miniCHOP in Older Non‐Fit Patients With Diffuse Large B‐Cell Lymphoma: Insights From a “Fondazione Italiana Linfomi” Cohort Study
par: Alberto Bavieri, et autres
Publié: (2025)

Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma
par: Meirav Kedmi, et autres
Publié: (2024)

Genetic and Transcriptomic Profiles Identify Potential Therapeutic Targets of Concurrent Follicular and Diffuse Large B‐Cell Lymphoma and Transformed Follicular Lymphoma
par: Rui Sun, et autres
Publié: (2026)

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third‐Line CAR T
par: Inna Y. Gong, et autres
Publié: (2026)

Follicular Lymphoma: Current Therapeutic Landscape and Future Prospects
par: Emil Kumar, et autres
Publié: (2025)

Therapy Sequencing in Relapsed/Refractory MCL
par: Eva Giné
Publié: (2025)

Clinical Outcomes of CD7 CAR‐T Cell Therapy in Relapsed or Refractory T‐Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients
par: Jinyan Xiao, et autres
Publié: (2025)

57 | CLONAL HEMATOPOIESIS IN FOLLICULAR LYMPHOMA: ANALYSIS OF THE PHASE III FIL FOLL12 TRIAL
par: R. Moia, et autres
Publié: (2025)

CAR T‐Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real‐World Experiences From a Single Center on the Use of Radiotherapy
par: J.T. Jutzi, et autres
Publié: (2025)

Advances in the Management of Relapsed/Refractory CLL and Richter Transformation
par: Nathalie Javidi‐Sharifi, et autres
Publié: (2025)

Efferocytosis and M2 Macrophage Polarization Gene Expression Correlates With Relapsed and Refractory Classical Hodgkin Lymphoma Patients: A Multi‐Omic Analysis
par: Juan Quarroz Braghini, et autres
Publié: (2025)

Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High‐Dose Cytarabine‐Based Chemotherapy as Second‐Line Treatments for Relapsed or Refractory Diffuse Large B‐Cell Lymphoma
par: Yoshikazu Ikoma, et autres
Publié: (2025)

Texture analysis of 18F‐FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement
par: Elisabetta M. Abenavoli, et autres
Publié: (2024)

Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis
par: Michèle Hoffmann, et autres
Publié: (2025)

NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort
par: Calogero Vetro, et autres
Publié: (2026)

Combining Total Metabolic Tumor Volume With Beta‐2‐Microglobulin Levels Predicts Outcomes in High‐Burden Follicular Lymphoma Patients
par: A. Zduniak, et autres
Publié: (2024)

Different Role of PET‐CT Evaluation in Newly Diagnosed Follicular Lymphoma Upon Rituximab‐Based Chemotherapy and Chemo‐Free Immunotherapy
par: Nan Wang, et autres
Publié: (2024)

Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis
par: Maria Livia Del Giudice, et autres
Publié: (2024)

Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real‐Life Multicenter Experience. Results From the REDOT_MCL Study
par: Francesca Maria Quaglia, et autres
Publié: (2026)

Correction to Elotuzumab Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended Follow‐Up of a Multicenter, Retrospective Real‐World Experience With 321 Cases Outside of Controlled Clinical Trials
Publié: (2025)

Discovery Science highlights from the 17th International Conference on Malignant Lymphoma
par: Gabriela Forestieri, et autres
Publié: (2024)

UMG1 Defines a Targetable Subset of T‐Cell Lymphomas and Enables Precision Immunotherapy With a First‐in‐Class CD3ε Bispecific Engager
par: Daniele Caracciolo, et autres
Publié: (2026)

TP53 ‐Mutated Acute Myeloid Leukemia: Unanswered Questions
par: Antonella Bruzzese, et autres
Publié: (2025)

RETRACTION: Burkitt Lymphoma Versus Diffuse Large B‐Cell Lymphoma: A Practical Approach
Publié: (2026)

Correction to “Defining and Addressing the Current Unmet Medical Needs for the Frontline Treatment of Advanced Stage Aggressive Large B‐Cell Lymphoma: A Perspective From an Ad Hoc Panel of Italian Experts”
Publié: (2025)

Peripheral T‐Cell Lymphoma: What's Next?
par: Sang Eun Yoon, et autres
Publié: (2025)

Current Status of Revisions to the Lugano Classification in Lymphoma
Publié: (2025)

Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—The MicroLinf Study
par: Beatrice Casadei, et autres
Publié: (2024)

Baseline Tumor Burden Assessed With AI‐Guided PET/CT Total Metabolic Tumor Volume (TMTV) and LDH Levels Predict Efficacy of CAR‐T in Aggressive B‐Cell Lymphoma
par: Eugenio Galli, et autres
Publié: (2024)

Clinicopathological Characteristics of Extranodal Marginal Zone Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT‐Lymphoma) of the Intestine: A Single Center Analysis
par: Oskar Steinbrecher, et autres
Publié: (2024)

Lomustine, Etoposide and Cyclophosphamide as Conditioning for Auto‐HCT in Lymphomas
par: Rafaella Cabral Samico, et autres
Publié: (2025)

Acalabrutinib in High‐Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real‐Life Experience
par: Idanna Innocenti, et autres
Publié: (2025)

Breaking Traditions: Evaluating Single Fraction Radiation in Indolent Lymphoma
par: Hazim S. Ababneh, et autres
Publié: (2024)

Nodular Lymphocyte‐Predominant Hodgkin Lymphoma: Update on Biology and Treatment
par: Peter Borchmann, et autres
Publié: (2025)

Indolent T‐Cell Lymphoma of the Gastrointestinal Tract Associated With Strongyloides Stercoralis Infection
par: Yue Zhao, et autres
Publié: (2025)

Marginal Zone Lymphoma: Treatment Update With a Focus on Systemic Approaches
par: Sonali M. Smith
Publié: (2025)